The efficacy of Tofacitinib was tested on 289 patients hospitalised with severe Covid across 15 locations in Brazil. Half of these patients received 10 mg twice daily plus standard of care which includes glucocorticoids, while the other half were prescribed placebo twice daily plus standard of care for up to 14 days.
The results published in the New England Journal of Medicine showed that after 28 days, tofacitinib lowered the death or respiratory failure by 63 per cent. Among patients on tofacitinib, only 18.1 per cent had the incidence of death or respiratory failure compared to placebo (29 per cent).
Deaths in the tofacitinib group occurred in 2.8 per cent of patients and in 5.5 per cent of those in the placebo group.
Serious side effects occurred in 14.1 percent in the tofacitinib group and in 12 percent in the placebo group.
“We are encouraged by the initial findings of our randomized trial of tofacitinib in patients hospitalized with Covid-19 pneumonia,” said Otavio Berwanger, Director of the Academic Research Organisation, Hospital Israelita Albert Einstein, which coordinated the trial in collaboration with Pfizer.
“These results provide new information which indicates that the use of tofacitinib when added to standard of care, which includes glucocorticoids, may further reduce the risk of death or respiratory failure in this patient population,” Berwanger added.
However, it is important to note that tofacitinib has not been approved or authorised for use by any regulatory authority worldwide for the treatment of Covid-19 and tofacitinib should not be used in patients with an active serious infection, the researchers said.
Source: IANS
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsBit.us is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
